Chlorothiazide

Short Description:

API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
Chlorothiazide 58-94-6

 

[Indication] 

1. For the management of hypertension, either as monotherapy or in combination with other antihypertensive agents.

2. For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

3. For the treatment of central or nephrogenic diabetes insipidus.

4. For the prevention of calcium-containing renal calculi by reducing urinary calcium excretion.


Product Detail

Product Tags

PRODUCT DETAIL

Background

Chlorothiazide is an inhibitor of carbonic anhydrase and is slightly less potent than acetazolamide. This compound has been shown to block reabsorption of sodium and chloride ions.

Description

Chlorothiazide is a diuretic and antihypertensive. (IC50=3.8 mM) Target: Others Chlorothiazide sodium (Diuril) is a diuretic used within the hospital setting or for personal use to manage excess fluid associated with congestive heart failure. It is also used as an antihypertensive. Most often taken in pill form, it is usually taken orally once or twice a day. In the ICU setting, chlorothiazide is given to diurese a patient in addition to furosemide (Lasix). Working in a separate mechanism than furosemide, and absorbed enterically as a reconstituted suspension administered through a nasogastric tube (NG tube), the two drugs potentiate one another.

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase

NCT03574857 University of Virginia Heart Failure|Heart Failure With Reduced Ejection Fraction|Heart Failure Acute|Cardiovascular Diseases June 2018

Phase 4

NCT02546583 Yale University|National Heart, Lung, and Blood Institute (NHLBI) Heart Failure August 2015

Not Applicable

NCT02606253 Vanderbilt University|Vanderbilt University Medical Center Heart Failure February 2016

Phase 4

NCT00004360 National Center for Research Resources (NCRR)|Northwestern University|Office of Rare Diseases (ORD) Diabetes Insipidus, Nephrogenic September 1995

NCT00000484 National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases April 1966

Phase 3

Chemical structure

Chlorothiazide

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.

PRODUCTION MANAGEMENT

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Japan Viswill Tablet Detector

cpf14-1

DCS Control Room

PARTNER

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation

  • Previous:
  • Next:

  • Write your message here and send it to us